PFE · 10-Q · 2026Q2 · Full report
Capital Return Program
PFIZER INC · 2026-08-04 · Importance 19 · Surprise 6 · In source text
Pfizer’s board declared a $0.43-per-share dividend in April 2026, paid on June 12, 2026. The board declared another $0.43-per-share dividend in June 2026, payable September 1, 2026. Pfizer had $3.3 billion remaining under its share-purchase authorization as of June 28, 2026, but made no repurchases during the first six months of 2026.
Key facts
- As of June 28, 2026, Pfizer's remaining share-purchase authorization was $3.3 billion, with no repurchases in the first six months of 2026. source
- In June 2026, Pfizer's Board of Directors declared a dividend of $0.43 per share, payable on September 1, 2026, to shareholders of record at the close of business on July 24, 2026. source
- In April 2026, Pfizer's Board of Directors declared a dividend of $0.43 per share, paid on June 12, 2026, to shareholders of record at the close of business on May 8, 2026. source
- Pfizer's capital allocation framework is based on three core pillars: reinvesting in the business, maintaining and over the long term growing the dividend, and in the future the potential to make share repurchases after de-levering the balance sheet. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| liability | negative | committed | — | In June 2026, Pfizer's Board of Directors declared a dividend of $0.43 per share, payable on September 1, 2026, to shareholders of record… |
| cash | negative | committed | — | In June 2026, Pfizer's Board of Directors declared a dividend of $0.43 per share, payable on September 1, 2026, to shareholders of record… |